Factor 8 Hemlibra denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for factor 8 hemlibra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Hemlibra — and Why You Can Appeal

Hemlibra (emicizumab-kxwh) is a specialty biologic for hemophilia A, and Aetna — like most commercial insurers — requires prior authorization before covering it. A prior-auth-required denial means either that authorization was not obtained before dispensing, or that the authorization request was submitted and denied because the documentation did not satisfy Aetna's coverage criteria. The appeal strategy differs depending on which scenario applies.

If no PA was submitted before dispensing: The appeal must argue that the clinical emergency or circumstances that led to dispensing without PA justify retroactive authorization. Gather documentation of the urgency.

If a PA was submitted and denied: The appeal is a standard medical-necessity challenge — address each unmet criterion with supporting documentation.

## Why This Denial Is Appealable

Prior-authorization requirements are administrative gatekeeping tools, not final clinical determinations. When the clinical record supports coverage under Aetna's own published criteria, a prior-auth denial must be reversed on appeal. External reviewers apply objective clinical standards and are not bound by administrative process failures.

## Federal Appeal Framework

• ERISA §503 (self-funded plans): Full-and-fair review; 180 days from denial to file internally.
• ACA §2719 (fully-insured plans): Independent external review after internal exhaustion; typically within four months of the final internal denial.
• Expedited review: If the patient is at imminent risk of a serious bleeding event, request expedited processing — typically 72-hour resolution at both the internal and external stages.

## Concrete Appeal Steps and Timeline

1. Obtain the denial notice and determine whether this is a retroactive denial or a PA denial. 2. Request Aetna's complete prior-authorization criteria for Hemlibra. 3. Audit the original PA submission or identify the retroactive authorization pathway. 4. Assemble documentation to address each unmet criterion or to justify retroactive authorization. 5. File the internal appeal within the stated deadline (Aetna typically sets a window shorter than 180 days for PA appeals). 6. Escalate to external review if denied internally.

## Documentation to Gather

• Diagnosis confirmation: Specialist-confirmed hemophilia A diagnosis with inhibitor status documented.
• Clinical severity: Annualized bleed rate, joint damage, prior hospitalization records.
• Prior-treatment history: Every prior prophylaxis or on-demand therapy — product, dates, outcomes — demonstrating the clinical pathway that led to Hemlibra.
• Prescriber medical-necessity letter: The treating hematologist should address each of Aetna's PA criteria point by point, citing the specific chart finding that satisfies each one.
• Urgency documentation (for retroactive appeals): Records of the clinical circumstances that necessitated treatment before PA could be obtained.

## Criteria-Mapping Structure

Obtain Aetna's PA criteria for Hemlibra from the plan's published coverage policy. List each criterion verbatim. In the adjacent column, cite the chart document, date, and exact finding that satisfies it. A structured one-to-one mapping significantly increases the probability of reversal and gives the external reviewer a clear, auditable record if the appeal reaches that stage.